These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32030484)

  • 21. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.
    Udager AM; Shi Y; Tomlins SA; Alva A; Siddiqui J; Cao X; Pienta KJ; Jiang H; Chinnaiyan AM; Mehra R
    Prostate; 2014 Sep; 74(12):1199-208. PubMed ID: 25043157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Autophagy promotes recurrence of nasopharyngeal carcinoma via inducing the formation of dormant polyploid giant cancer cells].
    Xia T; Ji Y; Lu YN; Xie HJ; You YW; You B
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Sep; 57(9):1102-1109. PubMed ID: 36177565
    [No Abstract]   [Full Text] [Related]  

  • 24. Polyploid giant cancer cells are dependent on cholesterol for progeny formation through amitotic division.
    White-Gilbertson S; Lu P; Esobi I; Echesabal-Chen J; Mulholland PJ; Gooz M; Ogretmen B; Stamatikos A; Voelkel-Johnson C
    Sci Rep; 2022 May; 12(1):8971. PubMed ID: 35624221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
    Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
    Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
    Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
    J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
    Matsubara N; Uemura H; Satoh T; Suzuki H; Nishiyama T; Uemura H; Hashine K; Imanaka K; Ozono S; Akaza H
    Jpn J Clin Oncol; 2014 Dec; 44(12):1216-26. PubMed ID: 25320340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AMPK-mTOR-Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells.
    You B; Xia T; Gu M; Zhang Z; Zhang Q; Shen J; Fan Y; Yao H; Pan S; Lu Y; Cheng T; Yang Z; He X; Zhang H; Shi M; Liu D; You Y
    Cancer Res; 2022 Mar; 82(5):846-858. PubMed ID: 34965934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
    Babcook MA; Akgul M; Margevicius S; MacLennan GT; Fu P; Abouassaly R; Gupta S
    Prostate; 2018 Jul; 78(10):714-723. PubMed ID: 29577356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
    Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
    Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
    J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
    Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
    Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
    Satoh T; Uemura H; Tanabe K; Nishiyama T; Terai A; Yokomizo A; Nakatani T; Imanaka K; Ozono S; Akaza H
    Jpn J Clin Oncol; 2014 Dec; 44(12):1206-15. PubMed ID: 25425730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.